These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30055223)

  • 21. Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry.
    Li Y; Hewitt D; Lentz YK; Ji JA; Zhang TY; Zhang K
    Anal Chem; 2014 May; 86(10):5150-7. PubMed ID: 24749737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Systematic Literature Review of Injection Site Pain Perception in Adult Patients Treated with Citrate-Free and Citrate-Containing Biologic Agents.
    Junker S; Ebert O; Bartsch R
    Curr Rheumatol Rev; 2023 Jun; 19(3):303-313. PubMed ID: 36043729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.
    Kerwin BA
    J Pharm Sci; 2008 Aug; 97(8):2924-35. PubMed ID: 17973307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the In-Use Stability of Monoclonal Antibody IV Admixtures Prepared from Drug Products Containing Polysorbate 20 Degraded by Host-Cell Lipases.
    Riccardi C; Carlson DP; Graham KS; Shameem M; Kamen DE
    J Pharm Sci; 2023 Dec; 112(12):3045-3055. PubMed ID: 37643700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic-induced urticaria due to polysorbate 20.
    Kato M; Oiso N; Uchida S; Yanagihara S; Sano H; Tohda Y; Kawada A
    J Dermatol; 2019 Jul; 46(7):e230-e232. PubMed ID: 30758866
    [No Abstract]   [Full Text] [Related]  

  • 26. Oxidation of polysorbates - An underestimated degradation pathway?
    Weber J; Buske J; Mäder K; Garidel P; Diederichs T
    Int J Pharm X; 2023 Dec; 6():100202. PubMed ID: 37680877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations.
    Martos A; Koch W; Jiskoot W; Wuchner K; Winter G; Friess W; Hawe A
    J Pharm Sci; 2017 Jul; 106(7):1722-1735. PubMed ID: 28302541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes.
    Dwivedi M; Blech M; Presser I; Garidel P
    Int J Pharm; 2018 Dec; 552(1-2):422-436. PubMed ID: 30300706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
    Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
    Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review.
    Caballero ML; Quirce S
    J Investig Allergol Clin Immunol; 2020; 30(6):400-408. PubMed ID: 32376520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Light-Induced Histidine Adducts to an IgG1 Molecule Via Oxidized Histidine Residue and the Potential Impact of Polysorbate-20 Concentration.
    Lei M; Quan C; Wang JY; Kao YH; Schöneich C
    Pharm Res; 2021 Mar; 38(3):491-501. PubMed ID: 33666838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate.
    Perino E; Freymond N; Devouassoux G; Nicolas JF; Berard F
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):664-666. PubMed ID: 29481891
    [No Abstract]   [Full Text] [Related]  

  • 33. Risk assessment of supply chain for pharmaceutical excipients with AHP-fuzzy comprehensive evaluation.
    Li M; Du Y; Wang Q; Sun C; Ling X; Yu B; Tu J; Xiong Y
    Drug Dev Ind Pharm; 2016 Apr; 42(4):676-684. PubMed ID: 26266963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of severe immediate type reaction to macrogol and polysorbate 60 after intravaginal drug application.
    Schwede K; Simon JC; Treudler R
    Eur J Dermatol; 2019 Jun; 29(3):329-331. PubMed ID: 31389792
    [No Abstract]   [Full Text] [Related]  

  • 35. Polysorbates 20 and 80 Degradation by Group XV Lysosomal Phospholipase A2 Isomer X1 in Monoclonal Antibody Formulations.
    Hall T; Sandefur SL; Frye CC; Tuley TL; Huang L
    J Pharm Sci; 2016 May; 105(5):1633-1642. PubMed ID: 27056628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein-Polydimethylsiloxane Particles in Liquid Vial Monoclonal Antibody Formulations Containing Poloxamer 188.
    Grapentin C; Müller C; Kishore RSK; Adler M; ElBialy I; Friess W; Huwyler J; Khan TA
    J Pharm Sci; 2020 Aug; 109(8):2393-2404. PubMed ID: 32194095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silicone Oil Particles in Prefilled Syringes With Human Monoclonal Antibody, Representative of Real-World Drug Products, Did Not Increase Immunogenicity in In Vivo and In Vitro Model Systems.
    Joh NH; Thomas L; Christian TR; Verlinsky A; Jiao N; Allotta N; Jawa V; Cao S; Narhi LO; Joubert MK
    J Pharm Sci; 2020 Jan; 109(1):845-853. PubMed ID: 31628922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic Properties of Novel Excipient Suggest Mechanism for Improved Performance in Liquid Stabilization of Protein Biologics.
    Katz JS; Nolin A; Yezer BA; Jordan S
    Mol Pharm; 2019 Jan; 16(1):282-291. PubMed ID: 30495962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.